Patent · US Active

Synthetic lethal drug combination for treating renal cell carcinoma

US10322133B2 · kind B2 · utility

0Cited by

0References

15Claims

0Family size

Assignees

COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES · FR
Institut National de la Sante et de la Recherche Medicale (INSERM) · FR

Inventors

Sofia Giacosa · Bourgoin-Jallieu, FR
Catherine Pillet · Le Pont-de-Claix, FR
Claude Cochet · Le Pont-de-Claix, FR
Odile Filhol · Le Pont-de-Claix, FR
Caroline Barette · Grenoble, FR
Emmanuelle Soleilhac · Voiron, FR

Key dates

Filing date	Sep 21, 2016
Grant date	Jun 18, 2019
Priority date	—
Expiry date	Sep 21, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention pertains to a novel treatment of renal cell carcinoma and other a solid tumors which harbor a VHL inactivation, based on the combination of a first agent inhibiting a protein kinase CK2 (CK2) and a second agent inhibiting an Ataxia Telangiectasia Mutated (ATM) kinase.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.